Tam Dang‐Tan - Concepedia

Author

Tam Dang‐Tan

Novo Nordisk (United States)

Also Known As

Dang-Tan,Tam, T Dang-Tan, T. Dang-Tan, TAM DANG-TAN, Tam Dang-Tan, Tam Dang‐Tan

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Novo Nordisk (United States)Novo Nordisk (Denmark)McGill University Public Health Agency of Canada McMaster University

About

Tam Dang‐Tan is an author at Novo Nordisk (United States) specializing in psychology, behavioral sciences, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Public Health	1	1	345
2	Social Sciences	1	1	345
3	Behavioral Sciences	1	1	345
4	Psychology	1	1	345
5	Autonomy	1	1	345

Tam Dang‐Tan

Publications

741

Citations

H-Index

Page 1

	Year	Citations
Self-management and behaviour modification in COPD Jean Bourbeau, Diane Nault, Tam Dang‐Tan Patient Education and Counseling Behaviour ModificationBehavioral SciencesBehavior ManagementSelf-managementBehavior Modification	2003	345
Delays in diagnosis and treatment among children and adolescents with cancer in Canada Tam Dang‐Tan, Helen Trottier, Leslie S. Mery, Pediatric Blood & Cancer	2008	111
Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States Sarah Ali, Tam Dang‐Tan, William J. Valentine, Advances in Therapy	2020	51
Determinants of delays in treatment initiation in children and adolescents diagnosed with leukemia or lymphoma in Canada Tam Dang‐Tan, Helen Trottier, Leslie S. Mery, International Journal of Cancer	2009	40
Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis Solomon Nuhoho, Jatin Gupta, Brian Bekker Hansen, Diabetes Therapy	2019	39
Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis B.B. Hansen, Solomon Nuhoho, Sarah Ali, Journal of Medical Economics	2020	34
Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective Dhvani Shah, Nancy Risebrough, Johnna Perdrizet, ClinicoEconomics and Outcomes Research	2018	24
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States Barnaby Hunt, Brian Bekker Hansen, Åsa Ericsson, Advances in Therapy	2019	24
Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population Jay Visaria, Chioma Uzoigwe, Caroline Swift, Clinical Therapeutics	2021	21
Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States Lars Wilkinson, Barnaby Hunt, Pierre Johansen, Diabetes Therapy	2018	16

Page 1